MONALEESA-7 Trial Follow-Up Shows Maintained, Improved Quality of Life, Work Productivity
Premenopausal women with HR-positive, HER2-negative advanced breast cancer experienced improved survival and quality of life with the addition of Kisqali to Zoladex and endocrine therapy to their treatment regimen.
Premenopausal women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer experienced substantial clinical benefit, while maintaining or improving work productivity with greater maintenance of quality of life, according to study findings presented at the 37th Annual Miami Breast Cancer Conference®.
“It is particularly important to understand survival benefits in the context of treatment impact on quality of life in premenopausal patients with (advanced breast cancer),” the researchers wrote. “It is also important to assess the impact of treatment on (quality of life) in a subset of the (intent-to-treat) population with only patients who received (Kisqali or placebo) plus a (nonsteroidal aromatase inhibitor), to reflect the indicated use of (Kisqali).”
The phase 3 MONALEESA-7 trial, a first-of-its-kind, evaluated the addition of Kisqali (ribociclib) to treatment with Zoladex (goserelin) and endocrine therapy (either a nonsteroidal aromatase inhibitor or tamoxifen) in premenopausal women with HR-positive, HER2-negative advanced breast cancer.
Internal server error